oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2021-20-4-146-151oncotomsk-1876Research ArticleОБЗОРЫREVIEWSОНКОГЕННАЯ ДИАГНОСТИКА И ТЕРАПИЯCANCER–INDUCED DIAGNOSTIC AND THERAPEUTIC INTERVENTIONSШапошниковА. В.ShaposhnikovA. V.

 доктор медицинских наук, профессор, главный научный сотрудник, отделение общей онкологии

SPIN-код: 8756-9438. Author ID (Scopus): 7005752070 

 Россия, 344037, г. Ростов-на-Дону, 14-я линия, 63 

 MD, DSc, Professor, Leading Researcher, Department of General Oncology

Author ID (Scopus) 7005752070 

 63, 14 line street, 344037, Rostov-on-don, Russia 

alexshap@donpac.ruhttps://orcid.org/0000-0003-3061-6108КитО. И.KitO. I.

 доктор медицинских наук, профессор, член-корреспондент РАН, генеральный директор

SPIN-код: 1728-0329. Researcher ID (WOS): U-2241-2017. Author ID (Scopus): 55994103100

 Россия, 344037, г. Ростов-на-Дону, 14-я линия, 63 

 MD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, General Director

Researcher ID (WOS): U-2241-2017. Author ID (Scopus): 55994103100 

 63, 14 line street, 344037, Rostov-on-don, Russia 

ДженковаЕ. А.DzhenkovaE. A.

 доктор биологических наук, доцент, ученый секретарь

SPIN-код: 6206-6222. Author ID (Scopus): 6507889745. Researcher ID (WOS): K-9622-2014 

 Россия, 344037, г. Ростов-на-Дону, 14-я линия, 63 

 DSc, Associate Professor

Author ID (Scopus): 6507889745. Researcher ID (WOS): K-9622-2014 

 63, 14 line street, 344037, Rostov-on-don, Russia 

ЛегостаеваК. В.LegostaevaK. V.

 студентка 5 курса

 Россия, 344037, г. Ростов-на-Дону, пер. Нахичеванский, 29 

 student

 29, Nakhchivansky lane, 344037, Rostov-on-don, Russia 

ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава РоссииРоссияNational Medical Research Centre of OncologyRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава РоссииРоссияNational Medical Research Centre for OncologyRussian FederationФГБ ОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияRostov State Medical University  Russian Federation202129082021204146151Copyright © Шапошников А.В., Кит О.И., Дженкова Е.А., Легостаева К.В., 20212021Шапошников А.В., Кит О.И., Дженкова Е.А., Легостаева К.В.Shaposhnikov A.V., Kit O.I., Dzhenkova E.A., Legostaeva K.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1876

Представлен систематизированный анализ мировой литературы, посвященной механизмам возникновения и развития «de novo» опухолевых очагов, вызванных негативными воздействиями физических и медикаментозных агентов на этапах профилактики, диагностики и лечения злокачественных новообразований различной локализации. Проведен поиск доступных источников, опубликованных за последние 5–6 лет в базах данных medline, elibrary, pubmed, из которых 34 включено в настоящий обзор. Компьютерная томография в диагностике и лучевая терапия в лечении злокачественных новообразований увеличивают риск возникновения вторых первичных опухолевых очагов в 1,5–3 раза. Высоким канцерогенным потенциалом обладают многие препараты для лечения хронических неопухолевых заболеваний. Онкогенность химиотерапевтических средств, особенно в многолетней перспективе, является значимой. Инвазивные диагностические и лечебные методы также потенциально туморогенны. Часть описанных негативных эффектов различных методов диагностики и лечения в онкологии следует отнести к «неизбежным онкоятрогениям», обусловленным спецификой злокачественного процесса, вследствие чего их применение требует взвешенного подхода и разумного ограничения.

 the purpose of the study was to analyze facts and mechanisms of the development of second malignancies after radiodiagnostic and radiotherapy procedures as well as after different medicamental treatments. the search for relevant articles published over the last 6 years was carried out using  medline, elibrary, pubmed databases, and 34 publications were included in this review. the risk of second malignancies from ct scans and radiation therapy is increased by 1.5–3 times in cancer patients. some drugs for  treatment of chronic non-oncology diseases and many chemotherapeutic agents possess high carcinogenic potential in longtime period. invasive diagnostic and treatment methods, especially organ transplantations, have  protumorogenic effects. some of the diagnostic and treatment methods used in oncology should be considered as «inevitable oncoiatrogenic». applications of these methods require reasonable limitations. 

ятрогенияпостлучевая и медикаментозная канцерогенностьонкогенные негативы инвазивных вмешательствiatrogeniapost-radiation malignancymedicamental carcinogenitysecond-primary tumorsReferencesMadia F., Worth A., Whelan M., Corvi R. Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment. Environ Int. 2019 Jul; 128: 417–429. doi: 10.1016/j.envint.2019.04.067.Madia F., Worth A., Whelan M., Corvi R. Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment. Environ Int. 2019 Jul; 128: 417–429. doi: 10.1016/j.envint.2019.04.067.What are the Radiation Risks from CT? [Internet]. URL: https://www.fda.gov/radiation-emitting-products/medical-x-ray-imaging/whatare-radiation-risks-ct (cited 22.05.2020).What are the Radiation Risks from CT? [Internet]. URL: https://www.fda.gov/radiation-emitting-products/medical-x-ray-imaging/whatare-radiation-risks-ct (cited 22.05.2020).Hong J.Y., Han K., Jung J.H., Kim J.S. Association of Exposure to Diagnostic Low-Dose Ionizing Radiation With Risk of Cancer Among Youths in South Korea. JAMA Netw Open. 2019 Sep 4; 2(9): e1910584. doi: 10.1001/jamanetworkopen.2019.10584.Hong J.Y., Han K., Jung J.H., Kim J.S. Association of Exposure to Diagnostic Low-Dose Ionizing Radiation With Risk of Cancer Among Youths in South Korea. JAMA Netw Open. 2019 Sep 4; 2(9): e1910584. doi: 10.1001/jamanetworkopen.2019.10584.Shao Y.H., Tsai K., Kim S., Wu Y.J., Demissie K. Exposure to Tomographic Scans and Cancer Risks. JNCI Cancer Spectr. 2019 Nov 14; 4(1): pkz072. doi: 10.1093/jncics/pkz072.Shao Y.H., Tsai K., Kim S., Wu Y.J., Demissie K. Exposure to Tomographic Scans and Cancer Risks. JNCI Cancer Spectr. 2019 Nov 14; 4(1): pkz072. doi: 10.1093/jncics/pkz072.Zelensky A.N., Schoonakker M., Brandsma I., Tijsterman M., van Gent D.C., Essers J., Kanaar R. Low dose ionizing radiation strongly stimulates insertional mutagenesis in a γH2AX dependent manner. PLoS Genet. 2020 Jan 16; 16(1): e1008550. doi: 10.1371/journal.pgen.1008550.Zelensky A.N., Schoonakker M., Brandsma I., Tijsterman M., van Gent D.C., Essers J., Kanaar R. Low dose ionizing radiation strongly stimulates insertional mutagenesis in a γH2AX dependent manner. PLoS Genet. 2020 Jan 16; 16(1): e1008550. doi: 10.1371/journal.pgen.1008550.Fernandez-Antoran D., Piedrafita G., Murai K., Ong S.H., Herms A., Frezza C., Jones P.H. Outcompeting p53-Mutant Cells in the Normal Esophagus by Redox Manipulation. Cell Stem Cell. 2019 Sep 5; 25(3): 329–341.e6. doi: 10.1016/j.stem.2019.06.011.Fernandez-Antoran D., Piedrafita G., Murai K., Ong S.H., Herms A., Frezza C., Jones P.H. Outcompeting p53-Mutant Cells in the Normal Esophagus by Redox Manipulation. Cell Stem Cell. 2019 Sep 5; 25(3): 329–341.e6. doi: 10.1016/j.stem.2019.06.011.Schultz C.H., Fairley R., Murphy L.S., Doss M. The Risk of Cancer from CT Scans and Other Sources of Low-Dose Radiation: A Critical Appraisal of Methodologic Quality. Prehosp Disaster Med. 2020 Feb; 35(1): 3–16. doi: 10.1017/S1049023X1900520X.Schultz C.H., Fairley R., Murphy L.S., Doss M. The Risk of Cancer from CT Scans and Other Sources of Low-Dose Radiation: A Critical Appraisal of Methodologic Quality. Prehosp Disaster Med. 2020 Feb; 35(1): 3–16. doi: 10.1017/S1049023X1900520X.Rombouts A.J.M., Hugen N., Elferink M.A.G., Poortmans P.M.P., Nagtegaal I.D., de Wilt J.H.W. Increased risk for second primary rectal cancer after pelvic radiation therapy. Eur J Cancer. 2020 Jan; 124: 142–151. doi: 10.1016/j.ejca.2019.10.022.Rombouts A.J.M., Hugen N., Elferink M.A.G., Poortmans P.M.P., Nagtegaal I.D., de Wilt J.H.W. Increased risk for second primary rectal cancer after pelvic radiation therapy. Eur J Cancer. 2020 Jan; 124: 142–151. doi: 10.1016/j.ejca.2019.10.022.Charas T., Taggar A., Zelefsky M.J. Second malignancy risk in prostate cancer and radiotherapy. Future Oncol. 2017 Feb; 13(5): 385–389. doi: 10.2217/fon-2016-0503.Charas T., Taggar A., Zelefsky M.J. Second malignancy risk in prostate cancer and radiotherapy. Future Oncol. 2017 Feb; 13(5): 385–389. doi: 10.2217/fon-2016-0503.Dracham C.B., Shankar A., Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018 Jun; 36(2): 85–94. doi: 10.3857/roj.2018.00290.Dracham C.B., Shankar A., Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018 Jun; 36(2): 85–94. doi: 10.3857/roj.2018.00290.Pottegård A., Pedersen S.A., Schmidt S.A.J., Hölmich L.R., Friis S., Gaist D. Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma. JAMA Intern Med. 2018 Aug 1; 178(8): 1120–1122. doi: 10.1001/jamainternmed.2018.1652.Pottegård A., Pedersen S.A., Schmidt S.A.J., Hölmich L.R., Friis S., Gaist D. Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma. JAMA Intern Med. 2018 Aug 1; 178(8): 1120–1122. doi: 10.1001/jamainternmed.2018.1652.Cheung K.S., Chan E.W., Wong A.Y.S., Chen L., Wong I.C.K., Leung W.K. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018 Jan; 67(1): 28–35. doi: 10.1136/gutjnl-2017-314605.Cheung K.S., Chan E.W., Wong A.Y.S., Chen L., Wong I.C.K., Leung W.K. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018 Jan; 67(1): 28–35. doi: 10.1136/gutjnl-2017-314605.Brusselaers N., Sadr-Azodi O., Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020 Apr; 55(4): 453–461. doi: 10.1007/s00535-019-01652-z.Brusselaers N., Sadr-Azodi O., Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020 Apr; 55(4): 453–461. doi: 10.1007/s00535-019-01652-z.Byrd J.B., Chertow G.M., Bhalla V. Hypertension Hot Potato –Anatomy of the Angiotensin-Receptor Blocker Recalls. N Engl J Med. 2019 Apr 25; 380(17): 1589–1591. doi: 10.1056/NEJMp1901657.Byrd J.B., Chertow G.M., Bhalla V. Hypertension Hot Potato –Anatomy of the Angiotensin-Receptor Blocker Recalls. N Engl J Med. 2019 Apr 25; 380(17): 1589–1591. doi: 10.1056/NEJMp1901657.Manolis A.S. Carcinogenic Impurities in Generic Sartans: An Issue of Authorities Control or a Problem with Generics? Rhythmos. 2019; 14(2): 23–6.Manolis A.S. Carcinogenic Impurities in Generic Sartans: An Issue of Authorities Control or a Problem with Generics? Rhythmos. 2019; 14(2): 23–6.FDA Requests Removal of All Ranitidine Products (Zantac) from the Market [Internet]. URL: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantacmarket (cited 22.05.2020).FDA Requests Removal of All Ranitidine Products (Zantac) from the Market [Internet]. URL: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantacmarket (cited 22.05.2020).Levitan D. FDA Warns of Bladder Cancer Risk From Diabetes Drug. [Internet]. URL: https://www.cancernetwork.com/view/fda-warnsbladder-cancer-risk-diabetes-drug (cited 22.05.2020).Levitan D. FDA Warns of Bladder Cancer Risk From Diabetes Drug. [Internet]. URL: https://www.cancernetwork.com/view/fda-warnsbladder-cancer-risk-diabetes-drug (cited 22.05.2020).Morch L.S., Scovlund C.W., Hannaford P.C., Iversen L., Fielding S., Lidegaard O. Contemporary Hormonal Conception and the Risk of Breast Cancer. N Engl J Med. 2017; 377: 2228–2239. doi: 10.1056/NEJMoa170032.Morch L.S., Scovlund C.W., Hannaford P.C., Iversen L., Fielding S., Lidegaard O. Contemporary Hormonal Conception and the Risk of Breast Cancer. N Engl J Med. 2017; 377: 2228–2239. doi: 10.1056/NEJMoa170032.Collaboration Group on Hormonal Factors in Brest Cancer. Type and timing of menopausal hormone Therapy and breast cancer risk. Lancet. 2019; 394: 1150–1168.doi: 10.1016/SO140-6736 (19) 31709-X.Collaboration Group on Hormonal Factors in Brest Cancer. Type and timing of menopausal hormone Therapy and breast cancer risk. Lancet. 2019; 394: 1150–1168.doi: 10.1016/SO140-6736 (19) 31709-X.Соленова Л.Г. Вторые первичные опухоли у онкологических больных: эпидемиология, роль противоопухолевой терапии. Успехи молекулярной онкологии. 2016; 3: 30–43. doi: 10-17650/2313-805x-2016-3-3-30-43.Solenova L.G. Second primary malignancies in cancer survivors: epidemiology, role of anticancer therapy. Advances in Molecular Oncology, 2016; 3: 30–43. (in Russian). doi: 10-17650/2313-805x-2016-3-3-30-43.Morton L.M., Dores G.M., Schonfeld S.J., Linet M.S., Sigel B.S., Lam C.J.K., Tucker M.A., Curtis R.E. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. JAMA Oncol. 2019 Mar 1; 5(3): 318–325. doi: 10.1001/jamaoncol.2018.5625.Morton L.M., Dores G.M., Schonfeld S.J., Linet M.S., Sigel B.S., Lam C.J.K., Tucker M.A., Curtis R.E. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. JAMA Oncol. 2019 Mar 1; 5(3): 318–325. doi: 10.1001/jamaoncol.2018.5625.Белицкий Г.А., Лесовая Е.А., Кирсанов К.И., Якубовская М.Г. Вторые первичные опухоли у онкологических больных: лекарственный канцерогенез в онкологии. Успехи молекулярной онкологии. 2016; 3: 44–55. doi: 10.17650/2313-805X-2016-3-3-44-55.Belitskiy G.A., Lesovaya E.A., Kirsanov K.I., Yakubovskaya M.G. Second primary malignancies of cancer patients: treatment-related carcinogenesis. Advances in Molecular Oncology. 2016; 3: 44–55. (in Russian). doi: 10.17650/2313-805X-2016-3-3-44-55.Schaapveld M., Aleman B.M., van Eggermond A.M., Janus C.P., Krol A.D., van der Maazen R.W., Roesink J., Raemaekers J.M., de Boer J.P., Zijlstra J.M., van Imhoff G.W., Petersen E.J., Poortmans P.M., Beijert M., Lybeert M.L., Mulder I., Visser O., Louwman M.W., Krul I.M., Lugtenburg P.J., van Leeuwen F.E. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. N Engl J Med. 2015; 373(26): 2499–511. doi: 10.1056/NEJMoa1505949.Schaapveld M., Aleman B.M., van Eggermond A.M., Janus C.P., Krol A.D., van der Maazen R.W., Roesink J., Raemaekers J.M., de Boer J.P., Zijlstra J.M., van Imhoff G.W., Petersen E.J., Poortmans P.M., Beijert M., Lybeert M.L., Mulder I., Visser O., Louwman M.W., Krul I.M., Lugtenburg P.J., van Leeuwen F.E. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. N Engl J Med. 2015; 373(26): 2499–511. doi: 10.1056/NEJMoa1505949.Turcotte L.M., Liu Q., Yasui Y., Henderson T.O., Gibson T.M., Leisenring W., Arnold M.A., Howell R.M., Green D.M., Armstrong G.T., Robison L.L., Neglia J.P. Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2019 Dec 1; 37(34): 3310–19. doi: 10.1200/JCO.19.00129.Turcotte L.M., Liu Q., Yasui Y., Henderson T.O., Gibson T.M., Leisenring W., Arnold M.A., Howell R.M., Green D.M., Armstrong G.T., Robison L.L., Neglia J.P. Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2019 Dec 1; 37(34): 3310–19. doi: 10.1200/JCO.19.00129.Shaked Y. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer. 2019 Dec; 19(12): 667–685. doi: 10.1038/s41568-019-0209-6.Shaked Y. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer. 2019 Dec; 19(12): 667–685. doi: 10.1038/s41568-019-0209-6.WHO. Clobal Surveillance and Monitoring System for Substandart and Falsified Medical Products. 2017. 73 p.WHO. Clobal Surveillance and Monitoring System for Substandart and Falsified Medical Products. 2017. 73 p.Karagiannis G.S., Condeelis J.S., Oktay M.H. ChemotherapyInduced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions. Cancer Res. 2019 Sep; 79(18): 4567–76. doi: 10.1158/0008-5472.CAN-19-1147.Karagiannis G.S., Condeelis J.S., Oktay M.H. ChemotherapyInduced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions. Cancer Res. 2019 Sep; 79(18): 4567–76. doi: 10.1158/0008-5472.CAN-19-1147.Backes Y., Seerden T.C.J., van Gestel R.S.F.E., Kranenburg O., Ubink I., Schiffelers R.M., van Straten D., van der Capellen M.S., van de Weerd S., de Leng W.W.J., Siersema P.D., Offerhaus G.J.A., Morsink F.H., Ramphal W., Terhaar Sive Droste J., van Lent A.U.G., Geesing J.M.J., Vleggaar F.P., Elias S.G., Lacle M.M., Moons L.M.G. Tumor Seeding During Colonoscopy as a Possible Cause for Metachronous Colorectal Cancer. Gastroenterology. 2019 Nov; 157(5): 1222–1232.e4. doi: 10.1053/j.gastro.2019.07.062.Backes Y., Seerden T.C.J., van Gestel R.S.F.E., Kranenburg O., Ubink I., Schiffelers R.M., van Straten D., van der Capellen M.S., van de Weerd S., de Leng W.W.J., Siersema P.D., Offerhaus G.J.A., Morsink F.H., Ramphal W., Terhaar Sive Droste J., van Lent A.U.G., Geesing J.M.J., Vleggaar F.P., Elias S.G., Lacle M.M., Moons L.M.G. Tumor Seeding During Colonoscopy as a Possible Cause for Metachronous Colorectal Cancer. Gastroenterology. 2019 Nov; 157(5): 1222–1232.e4. doi: 10.1053/j.gastro.2019.07.062.Shyamala K., Girish H.C., Murgod S. Risk of tumor cell seeding through biopsy and aspiration cytology. J Int Soc Prev Community Dent. 2014 Jan; 4(1): 5–11. doi: 10.4103/2231-0762.129446.Shyamala K., Girish H.C., Murgod S. Risk of tumor cell seeding through biopsy and aspiration cytology. J Int Soc Prev Community Dent. 2014 Jan; 4(1): 5–11. doi: 10.4103/2231-0762.129446.Alieva M., van Rheenen J., Broekman M.L.D. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin Exp Metastasis. 2018 Apr; 35(4): 319–331. doi: 10.1007/s10585-018-9896-8.Alieva M., van Rheenen J., Broekman M.L.D. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin Exp Metastasis. 2018 Apr; 35(4): 319–331. doi: 10.1007/s10585-018-9896-8.Mahale P., Engels E.A., Lynch C.F., Morton L.M. Cancer risk following post-transplant lymphoproliferative disorders in solid organ transplant recipients. Br J Haematol. 2019 Jul; 186(2): 347–351. doi: 10.1111/bjh.15828.Mahale P., Engels E.A., Lynch C.F., Morton L.M. Cancer risk following post-transplant lymphoproliferative disorders in solid organ transplant recipients. Br J Haematol. 2019 Jul; 186(2): 347–351. doi: 10.1111/bjh.15828.Park B., Yoon J., Choi D., Kim H.J., Jung Y.K., Kwon O.J., Lee K.G. De novo cancer incidence after kidney and liver transplantation: Results from a nationwide population based data. Sci Rep. 2019 Nov 20; 9(1): 17202. doi: 10.1038/s41598-019-53163-9.Park B., Yoon J., Choi D., Kim H.J., Jung Y.K., Kwon O.J., Lee K.G. De novo cancer incidence after kidney and liver transplantation: Results from a nationwide population based data. Sci Rep. 2019 Nov 20; 9(1): 17202. doi: 10.1038/s41598-019-53163-9.Goubran H.A., Elemary M., Radosevich M., Seghatchian J., El-Ekiaby M., Burnouf T. Impact of Transfusion on Cancer Growth and Outcome. Cancer Growth Metastasis. 2016 Mar 13; 9: 1–8. doi: 10.4137/CGM.S32797.Goubran H.A., Elemary M., Radosevich M., Seghatchian J., El-Ekiaby M., Burnouf T. Impact of Transfusion on Cancer Growth and Outcome. Cancer Growth Metastasis. 2016 Mar 13; 9: 1–8. doi: 10.4137/CGM.S32797.Cupit-Link M.C., Kirkland J.L., Ness K.K., Armstrong G.T., Tchkonia T., LeBrasseur N.K., Armenian S.H., Ruddy K.J., Hashmi S.K. Biology of premature ageing in survivors of cancer. ESMO Open. 2017 Dec 18; 2(5): e000250. doi: 10.1136/esmoopen-2017-000250.Cupit-Link M.C., Kirkland J.L., Ness K.K., Armstrong G.T., Tchkonia T., LeBrasseur N.K., Armenian S.H., Ruddy K.J., Hashmi S.K. Biology of premature ageing in survivors of cancer. ESMO Open. 2017 Dec 18; 2(5): e000250. doi: 10.1136/esmoopen-2017-000250.

The authors declare that there are no conflicts of interest present.